Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 2/20 | 0.48 |
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2006870 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL1330698 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| Benzene SCHEMBL27714747 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL7785939 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL41828 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| Hydrochloric Acid SCHEMBL3069393 | 0.81 | ABAT (0.53) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL11388483 | 0.80 | ERCC1 (0.46) | PTPN1ERCC1ERCC4ALDH1A1LMNA | |
| SCHEMBL8049927 | 0.80 | ERCC1 (0.46) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL8049928 | 0.80 | ERCC1 (0.46) | ERCC1ERCC4ALDH1A1LMNAPKM | |
| SCHEMBL2573296 | 0.80 | CA2 (0.48) | ERCC1ERCC4ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130143882-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2588477-A1 | QUINOLINES AS PI3K INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003278-A1 | QUINOLINES AS P13K INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ERCC5 3618/4885FEN1 4864/4885PTPN1 367/4885 |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ERCC5 3935/4885FEN1 4863/4885PTPN1 236/4885 |
| US-20130143882-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | PI4KB, PI4KA, PIK3C3 | ERCC5 2435/4885FEN1 4634/4885PTPN1 1096/4885 |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ERCC5 3935/4885FEN1 4863/4885PTPN1 236/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ERCC5 3784/4885FEN1 4844/4885PTPN1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.